Haleon PLC Completes Share Buyback Program Tranche

Haleon PLC Sponsored ADR ( (HLN) ) has provided an update.

On August 13, 2025, Haleon PLC announced the purchase and cancellation of 1,400,000 ordinary shares as part of the second tranche of its share buyback program, initially announced on July 31, 2025. This move is part of Haleon’s strategic efforts to optimize its capital structure and enhance shareholder value, reflecting positively on its market positioning and potentially impacting shareholder interests.

The most recent analyst rating on (HLN) stock is a Buy with a $13.40 price target. To see the full list of analyst forecasts on Haleon PLC Sponsored ADR stock, see the HLN Stock Forecast page.

Spark’s Take on HLN Stock

According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.

Haleon PLC’s overall stock score of 65 reflects a mixed outlook. Strong financial performance and strategic investments are offset by bearish technical signals and regional sales challenges, particularly in North America. The company’s valuation is moderate, aligning with its growth prospects. Continued focus on innovation and market expansion could enhance its position, but near-term challenges need to be addressed.

To see Spark’s full report on HLN stock, click here.

More about Haleon PLC Sponsored ADR

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a human touch. The company’s product portfolio includes major categories such as Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its well-known brands include Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.

Average Trading Volume: 14,430,770

Technical Sentiment Signal: Hold

Current Market Cap: $43.01B

Learn more about HLN stock on TipRanks’ Stock Analysis page.